SV2004001279A - Formulaciones farmaceuticas ref. pcs10964 - Google Patents
Formulaciones farmaceuticas ref. pcs10964Info
- Publication number
- SV2004001279A SV2004001279A SV2002001279A SV2002001279A SV2004001279A SV 2004001279 A SV2004001279 A SV 2004001279A SV 2002001279 A SV2002001279 A SV 2002001279A SV 2002001279 A SV2002001279 A SV 2002001279A SV 2004001279 A SV2004001279 A SV 2004001279A
- Authority
- SV
- El Salvador
- Prior art keywords
- pharmaceutical
- dimetoxi
- piridil
- tetrahydroisoquinol
- pharmaceutically acceptable
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 CHLORID HYDROGEN Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA INVENCION PROPORCIONA UNA FORMULACION FARMACEUTICA DE LIBERACION CONTROLADA PARA ADMINISTRAR ORALK QUE COMPRENDE 4-AMINO-6, 7-DIMETOXI-2-(5-METANOSULFONAMIDO- 1,2,3,4-TETRAHIDROISOQUINOL-2-IL) -5-(2-PIRIDIL) QUINAZOLINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, Y UN ADYUVANTE, DILUYENTE O VEHICULO FARMACEUTICA,MENTE ACEPTABLE, CARACTERIZADA PORQUE LA FORMULACION ESTA ADAPTADA PARA LIBERAR AL MENOS UN 50% EN PESO DE LA 4-AMINO-6, 7-DIMETOXI-2-( 5-METANOSILFONAMIDO-1,2,3,4-TETRAHIDROISOQUINOL-2-IL)-5-(2-PIRIDIL) QUINAZOLINA, O LA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, DESPUES DE 6 HORAS EN EL APARATO 1 DESCRITO EN LA FARMACOPEA DE ESTADOS UNIDOS 24(2000), PAGINAS 1941-1943, QUE TIENE RECIPIENTES DE 1 LITRO, CESTAS DE MALLA 40 ( ORIFICIOS DE 0,4 mm) UNA VELOCIDAD DE ROTACION DE 100 rpm Y UN MEDIO DE DISOLUCION QUE CONSTA DE 900ml DE ACIDO CLORHIDRICO 0, 01 M QUE CONTIENE CLORURO SODICO AL 0,7% p/v A 37°C. LAS FROMULACIONES DE ACUERDO CON LA INVENCION SON ADECUADAS PARA EL TRATAMIENTO DE LA BPH.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124455.7A GB0124455D0 (en) | 2001-10-11 | 2001-10-11 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2004001279A true SV2004001279A (es) | 2004-02-19 |
Family
ID=9923660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2002001279A SV2004001279A (es) | 2001-10-11 | 2002-10-10 | Formulaciones farmaceuticas ref. pcs10964 |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1434570B8 (es) |
| JP (1) | JP4131471B2 (es) |
| KR (1) | KR20050032510A (es) |
| CN (1) | CN1568180A (es) |
| AP (1) | AP2004003001A0 (es) |
| AR (1) | AR036782A1 (es) |
| AT (1) | ATE303135T1 (es) |
| BR (1) | BR0213196A (es) |
| CA (1) | CA2461168A1 (es) |
| CO (1) | CO5560534A2 (es) |
| DE (1) | DE60205925T2 (es) |
| DK (1) | DK1434570T3 (es) |
| DO (1) | DOP2002000464A (es) |
| EA (1) | EA006168B1 (es) |
| ES (1) | ES2246017T3 (es) |
| GB (1) | GB0124455D0 (es) |
| GT (1) | GT200200184A (es) |
| HR (1) | HRP20040261A2 (es) |
| HU (1) | HUP0600064A3 (es) |
| IL (1) | IL160969A0 (es) |
| IS (1) | IS7179A (es) |
| MA (1) | MA27075A1 (es) |
| MX (1) | MXPA04003293A (es) |
| NO (1) | NO20041520L (es) |
| OA (1) | OA12709A (es) |
| PA (1) | PA8556001A1 (es) |
| PE (1) | PE20030551A1 (es) |
| PL (1) | PL369666A1 (es) |
| SV (1) | SV2004001279A (es) |
| UY (1) | UY27477A1 (es) |
| WO (1) | WO2003032956A1 (es) |
| ZA (1) | ZA200401976B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| AP2015008789A0 (en) | 2013-03-14 | 2015-10-31 | Cytokinetics Inc | Heterocyclic compounds and their uses |
| KR101943592B1 (ko) | 2017-08-31 | 2019-01-30 | 조현우 | 데이터 마이닝 기법을 이용한 전자가계부 시스템 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0466986B1 (en) * | 1990-07-02 | 1994-04-27 | Bend Research, Inc. | Asymmetric microporous beads for controlled release |
| FR2752737B1 (fr) * | 1996-08-29 | 1998-10-02 | Synthelabo | Comprime a liberation controlee de chlorhydrate d'alfuzosine |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
| GEP20043364B (en) * | 2000-03-03 | 2004-03-10 | Pfizer | 4-Amino-6,7-Dimethoxy-2-(5-Methanesulfonamido-1,2,3,4- Tetrahydroisoquinol-2-Yl)-5-(2-Pyridyl) Quinazoline Mesylat And Polymorphs |
-
2001
- 2001-10-11 GB GBGB0124455.7A patent/GB0124455D0/en not_active Ceased
-
2002
- 2002-09-12 DO DO2002000464A patent/DOP2002000464A/es unknown
- 2002-09-17 GT GT200200184A patent/GT200200184A/es unknown
- 2002-09-30 HU HU0600064A patent/HUP0600064A3/hu unknown
- 2002-09-30 JP JP2003535760A patent/JP4131471B2/ja not_active Expired - Fee Related
- 2002-09-30 AT AT02775048T patent/ATE303135T1/de not_active IP Right Cessation
- 2002-09-30 CA CA002461168A patent/CA2461168A1/en not_active Abandoned
- 2002-09-30 OA OA1200400094A patent/OA12709A/en unknown
- 2002-09-30 EA EA200400431A patent/EA006168B1/ru not_active IP Right Cessation
- 2002-09-30 AP APAP/P/2004/003001A patent/AP2004003001A0/en unknown
- 2002-09-30 CN CNA02820042XA patent/CN1568180A/zh active Pending
- 2002-09-30 KR KR1020047005316A patent/KR20050032510A/ko not_active Application Discontinuation
- 2002-09-30 PL PL02369666A patent/PL369666A1/xx not_active Application Discontinuation
- 2002-09-30 BR BR0213196-0A patent/BR0213196A/pt not_active IP Right Cessation
- 2002-09-30 WO PCT/IB2002/004040 patent/WO2003032956A1/en active IP Right Grant
- 2002-09-30 ES ES02775048T patent/ES2246017T3/es not_active Expired - Lifetime
- 2002-09-30 DE DE60205925T patent/DE60205925T2/de not_active Expired - Lifetime
- 2002-09-30 DK DK02775048T patent/DK1434570T3/da active
- 2002-09-30 EP EP02775048A patent/EP1434570B8/en not_active Expired - Lifetime
- 2002-09-30 MX MXPA04003293A patent/MXPA04003293A/es active IP Right Grant
- 2002-09-30 IL IL16096902A patent/IL160969A0/xx unknown
- 2002-10-09 UY UY27477A patent/UY27477A1/es not_active Application Discontinuation
- 2002-10-09 AR ARP020103805A patent/AR036782A1/es unknown
- 2002-10-09 PE PE2002000996A patent/PE20030551A1/es not_active Application Discontinuation
- 2002-10-10 SV SV2002001279A patent/SV2004001279A/es not_active Application Discontinuation
- 2002-10-10 PA PA20028556001A patent/PA8556001A1/es unknown
-
2004
- 2004-03-11 IS IS7179A patent/IS7179A/is unknown
- 2004-03-11 ZA ZA200401976A patent/ZA200401976B/en unknown
- 2004-03-17 HR HR20040261A patent/HRP20040261A2/hr not_active Application Discontinuation
- 2004-03-18 CO CO04025929A patent/CO5560534A2/es not_active Application Discontinuation
- 2004-04-05 NO NO20041520A patent/NO20041520L/no unknown
- 2004-04-08 MA MA27623A patent/MA27075A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van Huijsduijnen et al. | The antimalarial pipeline | |
| CR8352A (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
| ATE464049T1 (de) | Pharmazeutische kombinationen von hydrocodon und naltrexon | |
| PE20050128A1 (es) | Formulacion farmaceutica | |
| BR0215184A (pt) | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada | |
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| BR0016012A (pt) | Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração | |
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| CY1109861T1 (el) | Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης | |
| PA8583301A1 (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
| ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
| BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
| DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
| DE60211139D1 (de) | Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp | |
| SV2002000235A (es) | Composiciones farmaceuticas que comprenden valdecoxib | |
| DE122006000057I2 (de) | Proteinhaltige arzneimittel | |
| SV2004001279A (es) | Formulaciones farmaceuticas ref. pcs10964 | |
| TW200503689A (en) | Pharmaceutical compositions of atorvastatin | |
| MXPA06007510A (es) | Composiciones de farmaco y formas de dosis novedosas de topiramato. | |
| AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
| BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
| PE20050699A1 (es) | Sistemas emulsionantes que contienen derivados de azetidina | |
| HUP0202931A2 (hu) | Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék | |
| BRPI0413374A (pt) | composições para liberação de base fraca por um perìodo estendido de tempo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |